Home › Compound Library › Pregabalin (Lyrica)

Pregabalin (Lyrica)

Anticonvulsantprescriptionoral · inferred

Alpha-2-delta calcium channel ligand structurally related to gabapentin but with more predictable linear pharmacokinetics and higher potency. Approved for neuropathic pain, fibromyalgia, partial seizures (adjunct), and generalized anxiety disorder (EU). Rapidly absorbed with >90% bioavailability (versus gabapentin's saturable absorption). Schedule V controlled substance due to mild euphoric/anxiolytic abuse potential.

Projected serum levels — 75 mg, twice daily

Pregabalin (Lyrica)
Pregabalin (Lyrica) modeled serum levels, 75 mg twice daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 25 50 75 100 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 75 mg twice daily (oral).

Modeled steady state after ~1 days: peak ≈ 53.0 mg, trough ≈ 6.1 mg body load. Population-based estimate over 15 days for a 75 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Anticonvulsant
Route modeled
Oral
Model confidence
inferred
Half-life
6.3 h
Common dose
75 mg
Suggested maximum
600 mg/day
Reference dose range
25–600 mg (single dose)
Suggested cadence
twice daily
Validated against
75 mg oral — Cmax 2 mg/L at 1 h

Documented interactions

  • watch
    Gabapentin (Neurontin) + Pregabalin (Lyrica) Stacked effects

    Gabapentin (Neurontin) and Pregabalin (Lyrica) both push the cacna2d in the same direction.

  • watch
    Lamotrigine (Lamictal) + Pregabalin (Lyrica) Stacked effects

    Lamotrigine (Lamictal) and Pregabalin (Lyrica) both push the cacna2d in the same direction.

  • watch
    Phenibut (beta-Phenyl-GABA) + Pregabalin (Lyrica) Stacked effects

    Phenibut (beta-Phenyl-GABA) and Pregabalin (Lyrica) both push the cacna2d in the same direction.

Serum checks 3 modeled interaction pairings for pregabalin (lyrica) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Pregabalin for the treatment of generalized anxiety disorder: a double-blind, placebo-controlled trial Feltner DE et al. · Journal of Clinical Psychopharmacology, 2003 DOI

    Pivotal RCT demonstrating pregabalin 150-600 mg/day significantly reduced HAM-A anxiety scores versus placebo, with anxiolytic effects evident by week 1 and comparable to alprazolam.

  2. A randomized, double-blind, placebo-controlled trial of pregabalin in the treatment of patients with fibromyalgia Crofford LJ et al. · Arthritis & Rheumatism, 2005 DOI

    Multicenter RCT (529 patients) establishing pregabalin 150-450 mg/day as effective for fibromyalgia pain, with 450 mg/day producing 29% reduction in pain score versus placebo.

  3. Clinical pharmacokinetics of pregabalin in healthy volunteers Bockbrader HN et al. · Journal of Clinical Pharmacology, 2010 DOI

    Definitive PK study establishing pregabalin half-life of 6.3 hours, >90% oral bioavailability, linear dose-proportional pharmacokinetics, negligible metabolism, and predominantly renal elimination.

3 published studies referenced in the app, each with a plain-language summary.